Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunities

6 Feb 2025

Abstract excerpt

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Chemotherapy remains the primary treatment option, yet TNBC frequently develops resistance, leading to relapse and metastasis. Emerging evidence highlights the potential of combining DNA methylation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Epigenetics and DNA Methylation
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39980537
DOI: 10.3389/fonc.2025.1534055

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunitiesPMID 39980537Read ↗

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast CancerSemantic proximity Read ↗

Targeting DNA Methylation for Treating Triple-Negative Breast CancerSemantic proximity Read ↗

Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancerSemantic proximity Read ↗

The DNA methylation landscape of primary triple-negative breast cancerSemantic proximity Read ↗

New Biomarkers and Treatment Advances in Triple-Negative Breast CancerSemantic proximity Read ↗

Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategiesSemantic proximity Read ↗

Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancerSemantic proximity Read ↗

Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectivesSemantic proximity Read ↗

Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment optionsSemantic proximity Read ↗

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypesSemantic proximity Read ↗

Advances in immunotherapy for triple-negative breast cancerSemantic proximity Read ↗

Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.